|1.||Boros, Mihály: 9 articles (08/2012 - 12/2006)|
|2.||Vance, Dennis E: 9 articles (12/2011 - 03/2004)|
|3.||Setou, Mitsutoshi: 8 articles (07/2015 - 01/2012)|
|4.||Stremmel, Wolfgang: 8 articles (07/2014 - 09/2007)|
|5.||Tang, W H Wilson: 7 articles (09/2015 - 04/2011)|
|6.||Hazen, Stanley L: 7 articles (02/2015 - 10/2006)|
|7.||Hayasaka, Takahiro: 7 articles (09/2014 - 01/2012)|
|8.||Ehehalt, Robert: 7 articles (09/2013 - 09/2007)|
|9.||Kaszaki, József: 7 articles (08/2012 - 12/2006)|
|10.||Ghyczy, Miklós: 6 articles (08/2012 - 01/2008)|
10/01/2014 - "Phosphatidylcholine (PC) is a key constituent of the intestinal mucus barrier, and exogenous PC administration has had therapeutic efficacy in patients with ulcerative colitis. "
07/01/2005 - "Retarded release oral phosphatidylcholine is effective in alleviating inflammatory activity caused by ulcerative colitis."
01/01/2014 - "This approach is based on decreased phosphatidylcholine concentrations in the colonic mucus in patients, and showed positive effects in a number of monocentric trials in steroid-refractory and chronic active ulcerative colitis. "
12/01/2010 - "Delayed release phosphatidylcholine as new therapeutic drug for ulcerative colitis--a review of three clinical trials."
05/01/2010 - "Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study."
09/20/1996 - "Based on these enzyme studies, we conclude that the high level of phosphatidylcholine in colon tumors resulted from a decrease in its turnover and an increase in its expression."
01/29/1990 - "These results analysed in the light of concomitant alterations in the levels of phospholipid precursors and catabolites (determined in previous 31P NMR studies) and histological modifications demonstrated that at early stages of TNF-induced inhibition of tumor growth (a) phospholipid catabolism was significantly enhanced; (b) morphological changes were apparently correlated with alterations in the levels of phosphatidylcholine and its catabolic products."
02/10/2015 - "Tumor cell death in vivo translating into liver tumor regression was associated with augmented phosphatidylcholine synthesis by the PEMT pathway, known as a liver-specific tumor suppressor, and restored mitochondrial function and TCA cycle flux. "
01/01/2015 - "Furthermore, bAT from tumor-bearing mice expressed higher phosphatidylcholines than that from non-tumor bearing mice, suggesting the presence of the tumor is associated with phosphatidylcholines. "
01/01/2013 - "This review will detail our current understanding of how coordinated changes in substrate availability, gene expression and enzyme activity lead to altered phosphatidylcholine synthesis in cancer, and how these changes contribute directly or indirectly to malignant growth. "
01/01/2007 - "Previous clinical study showed that a saturated phosphatidylcholine (SPC), dipalmitoyl-phosphatidylcholine (DPPC), was effective in the treatment of osteoarthritis, however recent studies suggested that the dominant SAPL species at some sites outside the lung are not SPC, rather, are unsaturated phosphatidylcholine (USPC). "
06/01/2010 - "A proprietary complex of curcumin with soy phosphatidylcholine (Meriva®, Indena SpA) was evaluated in a registry study to define its efficacy in 50 patients with osteoarthritis (OA) at dosages corresponding to 200 mg curcumin per diem. "
12/01/2010 - "Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients."
06/01/2010 - "Product-evaluation registry of Meriva®, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis."
12/01/2010 - "In a previous three-month study of Meriva, a proprietary curcumin-phosphatidylcholine phytosome complex, decreased joint pain and improvement in joint function were observed in 50 osteoarthritis (OA) patients. "
04/01/2013 - "The data indicate the essential role of the mucus phosphatidylcholine content for protection against inflammation in colon. "
02/01/2014 - "Recent studies about inflammation revealed that the signal at m/z 496.3 reflects lyso-phosphatidylcholine (LPC). "
06/01/2013 - "Protective effect of phosphatidylcholine on lipopolysaccharide-induced acute inflammation in multiple organ injury."
11/01/2011 - "Our goal was to characterize the neuroprotective properties of orally administered phosphatidylcholine (PC) in a rodent model of systemic inflammation. "
12/01/2008 - "Oral phosphatidylcholine preserves the gastrointestinal mucosal barrier during LPS-induced inflammation."
09/01/1990 - "Protective effects of phosphatidylcholine against mechanisms of ischemia and reperfusion-induced arrhythmias in isolated guinea pig ventricular tissues."
05/01/2007 - "The aims of this study were to characterize the effects of hindlimb ischemia-reperfusion (I-R) on the periosteal microcirculation and to define the consequences of systemic phosphatidylcholine (PC) therapy during this condition. "
12/01/2006 - "The aims of this study were to characterize the effects of hindlimb ischemia-reperfusion on the periosteal microcirculation and to define the consequences of systemic phosphatidylcholine therapy during this condition. "
11/01/2008 - "Oral phosphatidylcholine pretreatment decreases ischemia-reperfusion-induced methane generation and the inflammatory response in the small intestine."
12/01/2006 - "60 min of complete hindlimb ischemia was followed by a 180-min reperfusion in the presence of phosphatidylcholine treatment (50 mg/kg iv; in the second 10 min of reperfusion) or vehicle. "
|4.||Choline (Choline Chloride)
|5.||Apolipoprotein A-I (Apolipoprotein A1)
|10.||Cytidine Diphosphate Choline (Citicoline)
|1.||Drug Therapy (Chemotherapy)
|2.||Fluid Therapy (Oral Rehydration Therapy)